A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
What is the purpose of this trial?
This is a phase II single arm trial to evaluate the objective response rate of abemaciclib and letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer. Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
- Trial withGynecologic Oncology Group (GOG)
- Start Date02/16/2021
- End Date06/01/2022
- Last Updated07/15/2021
- Study HIC#2000028696